Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BQ50
UPID:
TREX2_HUMAN
Alternative names:
3'-5' exonuclease TREX2
Alternative UPACC:
Q9BQ50; Q45F08; Q9UN77
Background:
Three prime repair exonuclease 2 (TREX2), also known as 3'-5' exonuclease TREX2, plays a pivotal role in DNA repair mechanisms. It exhibits a preference for double-stranded DNA with mismatched 3' termini, highlighting its specificity in targeting and correcting DNA errors. This function is crucial for maintaining genomic stability and preventing mutations.
Therapeutic significance:
Understanding the role of Three prime repair exonuclease 2 could open doors to potential therapeutic strategies. Its involvement in DNA repair processes makes it a promising target for developing treatments aimed at enhancing DNA repair mechanisms, potentially offering new avenues for addressing genetic disorders.